ArticleProceedings of the National Academy of Sciences of the United States of America1994
Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 153 citations in OpenAlex.
- Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.Cancer gene therapy · 2017Article
- An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production.The Journal of biological chemistry · 2010Article
- The intrabody targeting of hTERT attenuates the immortality of cancer cells.Cellular & molecular biology letters · 2010Article
- Is gene therapy a good therapeutic approach for HIV-positive patients?Genetic vaccines and therapy · 2007Article
- Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G.Gene therapy · 2007Article
- Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor.Oncogene · 2003Article
- HIV-1 proprotein processing as a target for gene therapy.Gene therapy · 2003Article
- De novo production of diverse intracellular antibody libraries.Nucleic acids research · 2003Article
- The production and application of single-chain antibody fragments.Folia microbiologica · 2003Review
- Design and intracellular activity of a human single-chain antibody to human immunodeficiency virus type 1 conserved gp41 epitope.Journal of virology · 2000Article
- Gene therapy for HIV infections: Intracellular immunization.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 1999Article
- Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection.Gene therapy · 1999Article
- Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity.Plant molecular biology · 1998Review
- Chemokines and HIV-1 second receptors: the therapeutic connection.Nature medicine · 1998Review
- Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Gene therapy for infectious diseases.Clinical microbiology reviews · 1998Review
- Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.Journal of virology · 1997Article
- Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene.Journal of virology · 1997Article
- Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies.Journal of virology · 1997Article
- Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector.Journal of virology · 1997Article
Corrections and comments
- Correction · 1998-08-18Concerns/Issues about Data · Error in Analyses · Error in Results and/or Conclusions · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Objections by Author(s) · Unreliable Data · · This notice has 2 parts: a Correction by L Duan, MA Laughlin, JW Oakes, and RJ Pomerantz and a separate Correction/Comment by O Bagasra - they appear together.; The 2 Corrections/Comments appear on the same page of the journal, but have different dois - the doi for Bagasra's Comment is: 10.1073/pnas.95.17.10344-d.; There is a Findings of scientific misconduct notice for one author (L Duan) of this paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259619/.; The Reason field gathers reasons from both the Corrections/Comments and the PHS notice of misconduct.;
- Commented on by
- Commented on by
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Human immunodeficiency virus type 1 (HIV-1) has a complex life cycle, which has made it a difficult target for conventional therapeutic modalities. A single-chain antibody moiety, directed against the HIV-1 regulatory protein Rev, which rescues unspliced viral RNA from the nucleus of infected cells, has now been developed. This anti-Rev single-chain construct (SFv) consists of both light and heavy chain variable regions of anti-Rev monoclonal antibody, which, when expressed intracellularly within human cells, potently inhibits HIV-1 replication. This intracellular SFv molecule is demonstrated to specifically antagonize Rev function. Thus, intracellular SFv expression, against a retroviral regulatory protein, may be useful as a gene therapeutic approach to combat HIV-1 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.